Human Genome Epidemiology Literature Finder
Records 1 - 6 (of 6 Records) |
Query Trace: Thymoma and BRAF[original query] |
---|
AKT1 and AKT2 mutations in lung cancer in a Japanese population. Molecular medicine reports 0 1 (5): 663-6. Sasaki Hidefumi, Okuda Katsuhiro, Kawano Osamu, Yukiue Haruhiro, Yano Motoki, Fujii Yoshita |
Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling. Molecular cancer therapeutics 2012 Feb 11 (2): 485-91. Chaft Jamie E, Arcila Maria E, Paik Paul K, Lau Christopher, Riely Gregory J, Pietanza M Catherine, Zakowski Maureen F, Rusch Valerie, Sima Camelia S, Ladanyi Marc, Kris Mark |
Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer. Human pathology 2012 Oct 43 (10): 1573-82. Juanpere Nuria, Agell Laia, Lorenzo Marta, de Muga Silvia, López-Vilaró Laura, Murillo Raquel, Mojal Sergi, Serrano Sergio, Lorente José A, Lloreta Josep, Hernández Silv |
Mutational analysis of PI3K/AKT and RAS/RAF pathway activation in malignant salivary gland tumours with a new mutation of PIK3CA. International journal of oral and maxillofacial surgery 2016 Jan . Shalmon B, Drendel M, Wolf M, Hirshberg A, Cohen |
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs). Lung cancer (Amsterdam, Netherlands) 2017 Feb 104 24-30. Tiseo Marcello, Damato Angela, Longo Lucia, Barbieri Fausto, Bertolini Federica, Stefani Alessandro, Migaldi Mario, Gnetti Letizia, Camisa Roberta, Bordi Paola, Buti Sebastiano, Rossi Giul |
A mutation analysis of the EGFR pathway genes, RAS, EGFR, PIK3CA, AKT1 and BRAF, and TP53 gene in thymic carcinoma and thymoma type A/B3. Histopathology 2019 Jun . Sakane Tadashi, Murase Takayuki, Okuda Katsuhiro, Saida Kosuke, Masaki Ayako, Yamada Takeshi, Saito Yushi, Nakanishi Ryoichi, Inagaki Hiros |
- Page last reviewed:Feb 1, 2024
- Page last updated:Apr 22, 2024
- Content source: